Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04965259Active Not Recruiting

Early Detection of Hepatocellular Carcinoma in a High-risk Prospective Cohort (ELEGANCE)

Role: collaborator

NCT05148572Active Not Recruiting

Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma

Role: collaborator

NCT06504927Recruiting

Biomarker Discovery in Lung Cancer - Malaysia

Role: collaborator

NCT05633342Unknown

Project CADENCE (CAncer Detected Early caN be CurEd)

Role: lead

NCT04329299Completed

Use of Blood Biomarkers to Predict Gastric Cancer Risk

Role: collaborator

NCT02544490Completed

Defining Circulating Micro-RNA Biomarkers for the Early Diagnosis and Prognosis of Sepsis

Role: collaborator

All 6 trials loaded